Go to content

Newsroom

Recent news
Media Contact
GCI Health
Media enquiries

Contact us

Thank you for your interest in Medicago.

If you have any questions about our COVID-19 development program, including clinical trials, or the availability of Medicago shares, please click here to check our Frequently Asked Questions (FAQs). For any other questions, please complete the form below.

* Indicates required field.

Show more news
October 23, 2020
Press Release
Medicago signs agreements with the Government of Canada to supply up to 76 million doses of its recombinant plant-derived COVID-19 vaccine
July 14, 2020
Press Release
Medicago begins Phase I clinical trials for its COVID-19 vaccine candidate
July 8, 2020
Press Release
Dynavax and Medicago announce collaboration to develop a novel adjuvanted COVID-19 vaccine candidate
July 7, 2020
Press Release
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
May 14, 2020
Press Release
Medicago announces positive results in animal trials for its vaccine candidate against COVID-19
May 5, 2020
Press Release
Collaborative project of more than $1.2 million using artificial intelligence to optimize the production of vaccines, announced by CQDM and Medicago R&D
March 24, 2020
Press Release
Government of Canada providing financial support towards Medicago's COVID-19 vaccine development
March 21, 2020
Press Release
Government of Quebec providing $7 million towards Medicago's COVID-19 vaccine development
March 12, 2020
Press Release
Medicago announces production of a viable vaccine candidate for COVID-19
November 5, 2019
A Medicago's employee named one of CASCON x Evoke Canada's Tech Titans: Top 19 of 2019
October 1, 2019
Press Release
Medicago's New Drug Submission accepted for Scientific Review by Health Canada
April 25, 2019
Press Release
Medicago Awarded “Best New Vaccine Technology/Platform” at the World Vaccine Congress
March 20, 2019
Media Article
Congratulations Nathalie Landry as a finalist for the Mercuriades 2019 in the category Leadership, Outstanding Woman Sun Life Financial
December 20, 2018
Media Article
Canadian Biotech Breaking New Ground in the Fight Against Infectious Disease
October 30, 2018
Media Article
Life sciences - Québec International
September 27, 2018
Media Article
Return of U.S. Flu Season Brings Worries About a Virulent Replay (Bloomberg)
September 24, 2018
Media Article
Plant-Derived VLPs as a Novel Approach to Addressing an Unmet Need in Influenza Prevention
September 18, 2018
Press Release
Medicago officially starts the construction of its site in Estimauville's Innovation area
March 1, 2018
Media Article
This Company Is Testing a Flu Vaccine Made In Tobacco -- And Philip Morris Is On Board (Forbes)
September 26, 2017
Press Release
Medicago announces Phase 3 study of VLP Quadrivalent influenza vaccine
March 6, 2017
Press Release
Medicago's Board of Directors asked company CEO Andy Sheldon to explore new business opportunities for Medicago
October 29, 2015
Press Release
Medicago engaged by the Canadian Government to develop Ebola monoclonal antibodies
May 19, 2015
Press Release
Medicago to build $245M production facility in Quebec City

Be the first to know about Medicago news !

Sign up for our newsletter.

Scientific
publications

Transforming the approach
to vaccines and therapeutic proteins

Here are the current published studies and contributions
from Medicago's scientists and researchers.

Show more publications
October 13, 2020 Vaccine
Lancet publication: First human efficacy study of a plant-derived influenza vaccine
Authors: Brian J Ward, Alexander Makarkov, Annie Séguin, Stéphane Pillet, Sonia Trépanier, Jiwanjeet Dhaliwall, Michael D Libman, Timo Vesikari, Nathalie Landry
November 4, 2019 Vaccine
Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge
Authors: Breanna Hodgins, Stephane Pillet, Nathalie Landry and Brian J. Ward
June 5, 2019 Vaccine
Immunogenicity and safety of a quadrivalent plant-derived virus-like particle influenza vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and 50 years old adults
Authors: Stéphane Pillet, Julie Couillard, Sonia Trépanier, Jean-François Poulin, Bader Yassine-Diab, Bruno Guy, Brian J. Ward, Nathalie Landry
May 15, 2019 Vaccine
Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages
Authors: Makarkov, Makan Golizeh, Elizabeth Ruiz-Lancheros, Angelica A. Gopal, Ian N. Costas-Cancelas, Sabrina Chierzi, Stephane Pillet, Nathalie Charland, Nathalie Landry, Isabelle Rouiller, Paul W. Wiseman, Momar Ndao, and Brian J. Ward
October 31, 2018 Vaccine
Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutinin
Authors: So-Yoon Wona, Kristin Hunt, Hannah Guak, Benedeta Hasaj, Nathalie Charland, Nathalie Landry, Brian J. WardConnie M. Krawczyk
October 31, 2018 Vaccine
Investigation of an Adventitious Agent Test False Positive Signal in a Plant-Derived Influenza Vaccine
Authors: Todd L. Talarico, Michael Murphy, Raymond Nims, Dan Hastings, Jeri Ann Boose, and Dave Dumers
September 12, 2018 Vaccine
The adjuvant GLA-AF enhances human intradermal vaccine responses
Authors: Darrick Carter, Neal van Hoeven, Susan Baldwin, Yotam Levin, Efrat Kochba, Al Magill, Nathalie Charland, Nathalie Landry, Khin Nu, Aude Frevol, Jill Ashman, Zachary K. Sagawa, Anna Marie Beckmann, Steven G. Reed
April 24, 2018 Vaccine
Assessing the benefits of early pandemic influenza vaccine availability: a case study for Ontario, Canada
Authors: David Champredon, Marek Laskowski, Nathalie Charland & Seyed M. Moghadas
February 23, 2018 Vaccine
Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy.
Authors: Lindsay BJ, Bonar MM, Costas-Cancelas IN, Hunt K, Makarkov AI, Chierzi S, Krawczyk CM, Landry N, Ward BJ, Rouiller I.
January 16, 2018 Human Vaccines & Immunotherapeutics
The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?
Authors: Ward BJ, Pillet S, Charland N, Trepanier S, Couillard J, Landry N.
October 11, 2017 Vaccine
A single intramuscular dose of a plant-made virus-like-particle vaccine elicits a balanced humoral and cellular response and protects young and aged mice from influenza H1N1 challenge 4despite a modest/absent humoral response
Authors: Breanna Hodgins, Karen K Yam, Kaitlin Winter, Stephane Pillet, Nathalie Landry and Brian J. Ward
July 2, 2017 Vaccine
Plant-made virus-like particles bearing influenza hemagglutinin (HA) recapitulate early interactions of native influenza virions with human monocytes/macrophages.
Authors: Makarkov AI, Chierzi S, Pillet S, Murai KK, Landry N, Ward BJ
May 2, 2017 Human Vaccines & Immunotherapeutics
Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro.
Authors: Hendin HE, Pillet S, Lara AN, Wu CY, Charland N, Landry N, Ward BJ.
March 16, 2017 Vaccine
Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro
Authors: Hilary E. Hendin, Stéphane Pillet, Amanda N. Lara, Cheng-Ying Wua, Nathalie Charland, Nathalie Landry, Brian J. Ward
July 24, 2016 Vaccine
Cell wall biochemical alterations during Agrobacterium-mediated expression of haemagglutinin-based influenza virus-like vaccine particles in tobacco
Authors: Franccois Le Mauff, Corinne Loutelier-Bourhis, Muriel Bardor, Caroline Berard, Alain Doucet, Marc-André D'Aoust, Louis-Philippe Vezina, Azeddine Driouich, Manon M.-J. Couture and Patrice Lerouge
October 2, 2015 Vaccine
Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets
Authors: S. Pillet, T. Racine, C. Nfond, T.Z. Di Lenardob, S. Babiukd, B.J. Ward, G.P. Kobingerc, N. Landry
June 2, 2015
Generation and characterization of a trackable plant-made influenza H5 virus-like particle (VLP) containing enhanced green fluorescent protein (eGFP)
Authors: Katie R. Young, Guillaume Arthus-Cartier, Karen K. Yam, Pierre-Olivier Lavoie, Nathalie Landry, Marc-André D'Aoust, Louis-Philippe Vézina, Manon M.-J. Couture, and Brian J. Ward
April 21, 2015
Modulating secretory pathway pH by proton channel co-expression can increase recombinant protein stability in plants
Authors: Philippe V. Jutras, Marc-André D'Aoust, Manon M.-J. Couture, Louis-Philippe Vézina, Marie-Claire Goulet, Dominique Michaud, Frank Sainsbury
September 19, 2014
Human antibody response to N-glycans present on plant-madeinfluenza virus-like particle (VLP) vaccines
Authors: Brian J. Ward, Nathalie Landry, Sonia Trépanier, Geneviève Mercier,Michèle Dargis, Manon Couture, Marc-André D'Aoust, Louis-P. Vézinab
August 14, 2014
Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens
Authors: Nathalie Landry, Stéphane Pillet, David Favre, Jean-François Poulin, Sonia Trépanier, Bader Yassine-Diab, Brian J. Ward